Data from this study demonstrated that EZN-2208 treatment given as a single dose or in multiple dose regimen can cure animals bearing human non-Hodgkin’s lymphoma. EZN-2208 treatment cured animals and outperformed CPT-11, in very aggressive and advance disease preclinical models.
SN38 is the active metabolite of the widely used cancer drug CPT-11, marketed as Camptosar in the US.
Jeffrey Buchalter, chairman and CEO of Enzon, said: “The data further demonstrated the novel characteristics of our pegylated form of SN38, as this type of response by this class of drugs in NHL models is not expected.”